Drug profile · INN
alogliptin benzoate
VIPIDIA
alogliptin benzoate (VIPIDIA) is a dipeptidyl peptidase iv inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Drug details — alogliptin benzoate
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 20
- Programs
- 16
- Data quality
- 0.89
Quick answer
alogliptin benzoate (VIPIDIA) is a dipeptidyl peptidase iv inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Primary target: Dipeptidyl peptidase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12421188
Heterocyclic compound and use thereof
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12391765
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
granted -
US 12391760
Method of treating primary sclerosing cholangitis
granted -
US 12384770
Heterocyclic compound
granted -
US 12383587
AAV triple-plasmid system
granted -
US 12378256
Heterocyclic compound
granted -
US 12358879
Heterocyclic compound
granted -
US 12337020
Bacteriophage compositions
granted -
US 12319940
Methods for purification of arylsulfatase A
granted -
US 12290531
Compositions targeting BCMA and methods of use thereof
granted -
US 12286456
Purification of virus like particles
granted -
US 12281073
Substituted piperidine compound and use thereof
granted -
US 12202797
Method for producing pyrrole compound
granted -
US 12201683
Methods for preventing dengue and hepatitis a
granted -
US 12188948
Metabolite biomarkers for diseases associated with the contact activation system
granted -
US 12171777
Methods of making a cyclic dinucleotide
granted -
US 12171832
Methods of treating ulcerative colitis
granted -
US 12168041
Methods and compositions for CNS delivery of arylsulfatase A
granted
Frequently asked questions
What is alogliptin benzoate?
alogliptin benzoate (VIPIDIA) is a dipeptidyl peptidase iv inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for alogliptin benzoate?
VIPIDIA is a marketed brand name for alogliptin benzoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of alogliptin benzoate?
alogliptin benzoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.